GDTT1.8NAS12-HFE Gene Therapy Vector for HFE Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy vectors for treating HFE gene-related disorders, such as haemochromatosis, face challenges including the presence of antibiotic resistance genes, viral regulatory elements, and excessive length, which can lead to reduced efficiency and safety concerns.
Innovation Solution
The development of a gene therapy DNA vector, GDTT1.8NAS12-HFE, which lacks antibiotic resistance genes and viral regulatory elements, and has a minimized length to enhance penetration into eukaryotic cells, thereby safely and effectively increasing HFE gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional gene therapy vectors are used, then gene delivery capability is achieved, but the vectors contain antibiotic resistance genes and viral regulatory elements that reduce safety
Solution Approach 1:
The patent extracts and removes harmful components (antibiotic resistance genes and viral regulatory elements) from the gene therapy vector, retaining only the essential therapeutic elements. This extraction principle directly resolves the safety concern by eliminating the harmful factors while preserving the gene delivery function.
2Reliability
If conventional gene therapy vectors are used, then gene delivery is achieved, but excessive length reduces penetration efficiency into eukaryotic cells
Solution Approach 1:
The patent removes unnecessary and excessive sequence elements from the vector construct, retaining only the minimal essential components required for gene therapy function. This length minimization through extraction directly improves penetration efficiency into eukaryotic cells by reducing the vector size to an optimal range.
3Ease of manufacture
If antibiotic resistance genes are included in the vector, then bacterial selection during production is enabled, but safety concerns arise from potential horizontal gene transfer
Solution Approach 1:
The patent extracts and eliminates antibiotic resistance genes from the vector construct, removing the source of potential horizontal gene transfer risk. The production process is subsequently optimized to achieve bacterial selection through alternative methods that do not require antibiotic resistance markers, thus resolving the safety concern while maintaining manufacturability.
4Productivity
If viral regulatory elements are included in the vector, then gene expression enhancement is achieved, but safety and immunogenicity concerns increase
Solution Approach 1:
The patent removes viral regulatory elements from the vector construct, eliminating the source of immunogenicity and safety concerns. Alternative non-viral regulatory sequences are employed to achieve the necessary gene expression levels, thus resolving the contradiction between expression enhancement and safety/immunogenicity reduction.
Data Source
AI summary
Proposed is a gene-therapy DNA vector based on gene-therapy DNA vector GDTT1.8NAS12 for treating diseases characterized by impaired functioning of the HFE protein responsible for regulating iron metabolism in the human body, and for treating diseases related to impaired expression of the HFE gene, inter alia diseases caused by insufficient expression of the HFE gene and/or by the presence of mutations in the HFE gene, inter alia in the case of haemochromatosis, wherein the gene-therapy DNA vector contains the coding part of the target gene HFE, cloned in gene-therapy DNA vector GDTT1.8NAS12 to produce gene-therapy DNA vector GDTT1.8NAS12-HFE having the nucleotide sequence SEQ ID NO: 1. The resulting gene-therapy DNA vector GDTT1.8NAS12-HFE is capable of effectively penetrating into human and animal cells and expressing the target gene cloned in it, i.e. HFE, by virtue of the limited size of the vector part GDTT1.8NAS12, which is not greater than 2600 bp. In the proposed gene-therapy DNA vector GDTT1.8NAS12-HFE, nucleotide sequences which are not antibiotic resistance genes, viral genes or regulatory elements of viral genomes are used as structural elements, thus allowing the gene-therapy DNA vector to be used safely for gene therapy in humans and animals.